Biologics Center 510(k) Reviews Show Improvement In Early Fiscal ’03 – CBER
This article was originally published in The Gray Sheet
Executive Summary
Increased willingness by Center for Biologics Evaluation & Research reviewers to participate in interactive reviews could help reduce review cycles and times for devices and in vitro diagnostics at the biologics center, attorney Jonathan Kahan suggested
You may also be interested in...
CBER Review “Paradigm Shift” Credited With Improved Cycle/Review Stats
The Center for Biologics Evaluation & Research is working to identify problems with premarket applications earlier so they can be resolved in the first cycle of review, according to Robert Yetter, CBER associate director for review management
CBER Review “Paradigm Shift” Credited With Improved Cycle/Review Stats
The Center for Biologics Evaluation & Research is working to identify problems with premarket applications earlier so they can be resolved in the first cycle of review, according to Robert Yetter, CBER associate director for review management
MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2